Trevi Therapeutics Inc (TRVI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.95B
Last updated: Nov 17, 2026 at 11:06 AM ET
Trevi Therapeutics Inc (TRVI) Earnings: Report Dates and Results
Trevi Therapeutics (TRVI) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, Trevi Therapeutics reported EPS of -$0.13, in line with the -$0.13 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TRVI has an expected report date of Mar 15, 2027.
TRVI Earnings Call
The latest TRVI earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 30 quarters below that had an estimate, TRVI beat 20, missed 7 and matched 3. The widest gap in the table came in the quarter ended Dec 31, 2022, when EPS landed 40.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.13 | -$0.13 | -$0.18 - -$0.11 | 0.00% | In line | N/A | 10 | 0 up, 1 down | Nov 9, 2026 |
| Jun 30, 2026 | -$0.11 | -$0.11 | -$0.13 - -$0.10 | 0.00% | In line | N/A | 10 | 2 up, 1 down | Aug 6, 2026 |
| Mar 31, 2026 | -$0.09 | -$0.07 | -$0.10 - -$0.05 | -28.57% | Miss | N/A | 10 | N/A | May 5, 2026 |
| Dec 31, 2025 | -$0.06 | -$0.10 | -$0.11 - -$0.08 | +39.09% | Beat | N/A | 9 | 4 up, 0 down | Mar 17, 2026 |
| Sep 30, 2025 | -$0.08 | -$0.10 | -$0.12 - -$0.09 | +20.00% | Beat | N/A | 8 | 1 up, 0 down | Nov 13, 2025 |
| Jun 30, 2025 | -$0.09 | -$0.10 | -$0.12 - -$0.08 | +10.00% | Beat | N/A | 8 | 1 up, 0 down | Aug 7, 2025 |
| Mar 31, 2025 | -$0.09 | -$0.12 | -$0.15 - -$0.10 | +25.00% | Beat | N/A | 6 | N/A | May 8, 2025 |
| Dec 31, 2024 | -$0.11 | -$0.12 | -$0.13 - -$0.11 | +6.06% | Beat | N/A | 7 | 1 up, 1 down | Mar 18, 2025 |
| Sep 30, 2024 | -$0.13 | -$0.11 | -$0.13 - -$0.09 | -18.18% | Miss | N/A | 9 | 0 up, 0 down | Nov 6, 2024 |
| Jun 30, 2024 | -$0.12 | -$0.11 | -$0.11 - -$0.09 | -9.09% | Miss | N/A | 5 | 1 up, 0 down | Aug 8, 2024 |
| Mar 31, 2024 | -$0.11 | -$0.09 | -$0.09 - -$0.08 | -22.22% | Miss | N/A | 5 | 0 up, 0 down | May 7, 2024 |
| Dec 31, 2023 | -$0.08 | -$0.09 | -$0.11 - -$0.08 | +11.11% | Beat | N/A | 6 | 0 up, 0 down | Mar 20, 2024 |
| Sep 30, 2023 | -$0.08 | -$0.09 | -$0.10 - -$0.08 | +11.11% | Beat | N/A | 6 | 0 up, 0 down | Nov 9, 2023 |
| Jun 30, 2023 | -$0.07 | -$0.09 | -$0.10 - -$0.06 | +22.22% | Beat | N/A | 6 | 0 up, 0 down | Aug 10, 2023 |
| Mar 31, 2023 | -$0.06 | -$0.07 | -$0.09 - -$0.06 | +14.29% | Beat | N/A | 6 | 0 up, 0 down | May 11, 2023 |
| Dec 31, 2022 | -$0.06 | -$0.10 | -$0.13 - -$0.08 | +40.00% | Beat | N/A | 5 | 0 up, 0 down | Mar 16, 2023 |
| Sep 30, 2022 | -$0.12 | -$0.13 | -$0.18 - -$0.12 | +7.69% | Beat | N/A | 4 | 0 up, 0 down | Nov 10, 2022 |
| Jun 30, 2022 | -$0.14 | -$0.18 | N/A | +22.22% | Beat | N/A | N/A | 0 up, 0 down | Aug 11, 2022 |
| Mar 31, 2022 | -$0.24 | -$0.29 | -$0.31 - -$0.27 | +17.24% | Beat | N/A | 3 | 0 up, 0 down | May 12, 2022 |
| Dec 31, 2021 | -$0.28 | -$0.30 | -$0.34 - -$0.25 | +6.67% | Beat | N/A | 2 | 0 up, 0 down | Mar 17, 2022 |
| Sep 30, 2021 | -$0.34 | -$0.39 | -$0.46 - -$0.33 | +12.82% | Beat | N/A | 2 | N/A | Nov 10, 2021 |
| Jun 30, 2021 | -$0.49 | -$0.46 | -$0.46 - -$0.46 | -6.52% | Miss | N/A | 2 | N/A | Aug 12, 2021 |
| Mar 31, 2021 | -$0.43 | -$0.52 | -$0.56 - -$0.49 | +17.31% | Beat | N/A | 3 | N/A | May 13, 2021 |
| Dec 31, 2020 | -$0.51 | -$0.44 | -$0.47 - -$0.41 | -15.91% | Miss | N/A | 3 | N/A | Mar 25, 2021 |
| Sep 30, 2020 | -$0.41 | -$0.51 | -$0.67 - -$0.43 | +19.61% | Beat | N/A | 4 | N/A | Nov 12, 2020 |
| Jun 30, 2020 | -$0.41 | -$0.48 | -$0.52 - -$0.42 | +14.58% | Beat | N/A | 4 | N/A | Aug 13, 2020 |
| Mar 31, 2020 | -$0.48 | -$0.44 | -$0.46 - -$0.42 | -9.09% | Miss | N/A | 4 | N/A | May 7, 2020 |
| Dec 31, 2019 | -$0.37 | -$0.51 | -$0.59 - -$0.44 | +27.45% | Beat | N/A | 4 | N/A | Mar 16, 2020 |
| Sep 30, 2019 | -$0.41 | -$0.47 | -$0.52 - -$0.44 | +12.77% | Beat | N/A | 4 | N/A | Nov 14, 2019 |
| Jun 30, 2019 | -$0.41 | -$0.41 | -$0.45 - -$0.36 | 0.00% | In line | N/A | 4 | N/A | Aug 12, 2019 |
| Mar 31, 2019 | -$13.85 | -$0.52 | -$0.63 - -$0.29 | N/A | N/A | N/A | 4 | N/A | May 8, 2019 |
| Dec 31, 2018 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Feb 27, 2019 |
| Sep 30, 2018 | -$0.59 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 21, 2018 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.32, after -$0.47 the year before. It was -$0.59 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.32 | N/A |
| Dec 31, 2024 | -$0.47 | N/A |
| Dec 31, 2023 | -$0.29 | N/A |
| Dec 31, 2022 | -$0.56 | N/A |
| Dec 31, 2021 | -$1.54 | N/A |
| Dec 31, 2020 | -$1.81 | N/A |
| Dec 31, 2019 | -$15.04 | N/A |
| Dec 31, 2018 | -$0.59 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,900 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,852 | 16 | |
| 2026Q1 | Mar 31, 2026 | 4,636 | 13 | |
| 2025Q4 | Dec 31, 2025 | 6,605 | 15 | |
| 2025Q3 | Sep 30, 2025 | 5,375 | 12 | |
| 2025Q2 | Jun 30, 2025 | 5,491 | 15 | |
| 2025Q1 | Mar 31, 2025 | 4,242 | 12 | |
| 2024Q4 | Dec 31, 2024 | 4,750 | 11 | |
| 2024Q3 | Sep 30, 2024 | 4,252 | 10 |
2026Q3 Earnings Call
Opening remarks
Jennifer Good President and CEO Good afternoon, and thank you for joining us for our third quarter 2026 earnings call and business update. Joining me today on this call are my colleagues, Dr. James Cassella, our Chief Development Officer; Farrell Simon, our Chief Commercial Officer; and David Hastings, our Chief Financial Officer. Dave and I will make some initial comments, and then the team is happy to answer any questions you may have. 2026 is a busy year of execution for the company, and the team is heads down on initiating and executing clinical trials in each of our programs. This includes activating sites globally, focusing on ensuring enrollment stays on track, all while staying aligned with the regulatory authorities. It has been fast-paced, but this is the fun part of what we do. Let me provide a brief update on each of our programs. First, our lead program in IPF-related chronic cough. We have initiated both OCEAN-1 and OCEAN-2 trials. We are now approved by all regulatory authorities in each of the countries in which we are conducting clinical trials, and the clinical team is focused on getting all the sites activated and screening patients. We will give an update once we reach 50% of the patients randomized in each of these trials. The trials are in early stages and progressing, and we continue to believe we are on track with our previously stated guidance for OCEAN-2, the 12-week study reading out in the second half of 2027, and OCEAN-1, the 24-week efficacy endpoint with 52 weeks of safety reading out in the first half of 2028. In October, we took an important step forward in our non-IPF-ILD cough program by aligning with the FDA on the development plan and next study. The pulmonary division has been very helpful and supportive as we think about how to get the first chronic cough drug approved in the U.S. The discussions have been collaborative and clear. Following this meeting with the FDA, our plan is to conduct a Phase II dose-ranging study with approximately 120 non-IPF-ILD patients to confirm the optimal dose or doses to take forward into Phase III. The protocol is written and will be submitted back to the FDA for any comments. We also have the wheels in motion, identifying sites and working with our CRO partner to prepare for study initiation. Recall that these clinical centers will overlap directly with the same sites we are using in our North American IPF Phase III program. When we signed a contract and negotiated budgets for our OCEAN trials, we planned for the fact that we likely would conduct an ILD trial. We are planning to initiate this trial in the first quarter of 2027.
Frequently Asked Questions About TRVI
When is Trevi Therapeutics's next earnings date?
Trevi Therapeutics's next earnings report is expected for Mar 15, 2027.
Did TRVI beat earnings estimates last quarter?
Trevi Therapeutics reported EPS of -$0.13 for the quarter ended Sep 30, 2026, in line with the -$0.13 estimate.
What EPS do analysts expect from TRVI next quarter?
The consensus EPS estimate for Trevi Therapeutics for the quarter ending Dec 31, 2026 is -$0.15 from 14 analysts, with estimates from -$0.18 to -$0.12.
How often does TRVI beat earnings estimates?
Trevi Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +8.95%.
TRVI pages: Overview, Earnings, Forecast, Financials, Competitors